BAY-ACC001

BAY-ACC001 is a novel, selective small molecule inhibitor of acetyl-CoA carboxylase (ACC), specifically targeting the isoforms ACC1 and ACC2. Developed by Bayer, it is a ketoenol derivative designed to regulate de novo fatty acid synthesis and lipid survival signaling, which are frequently upregulated in various human tumors to support rapid proliferation. Preclinical studies have demonstrated that BAY-ACC001 potently inhibits malonyl-CoA synthesis and exhibits significant anti-proliferative activity across a range of tumor cell lines, including breast, prostate, colon, and melanoma models. Its mechanism of action involves the induction of apoptosis, potentially through the modulation of lipid signaling molecules such as ceramides. In vivo, BAY-ACC001 has shown efficacy as a single agent and synergistic effects when combined with tamoxifen in breast cancer models, providing a strong rationale for targeting ACC in oncology.